An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
about
Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primerIL-17RC: a partner in IL-17 signaling and beyondChemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosisUstekinumabReview of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasisApilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasisIFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hostsRole of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages.Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis.Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cellsImmunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumabOverrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis.Potential role of ustekinumab in the treatment of chronic plaque psoriasisInflammatory skin disease in K5.hTGF-beta1 transgenic mice is not dependent on the IL-23/Th17 inflammatory pathway.IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells.Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasisCurrent status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.The role of dendritic cells in tissue-specific autoimmunity.Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice.CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.Th17 cells in human disease.IL12p40 regulates functional development of human CD4+ T cells: enlightenment by the elevated expressions of IL12p40 in patients with inflammatory bowel diseasesp19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells.IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.Antimicrobial peptides in the pathogenesis of psoriasis.Pathogenesis and therapy of psoriasis.Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities.Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis.Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.Explaining phenotype heterogeneity in patients with psoriasis.Immune response profiles in human skin.Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines.Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications.Review paper: preclinical models of psoriasis.Th17 cells: a new therapeutic target in inflammatory dermatoses.Th17 cells: a new paradigm for cutaneous inflammation.Ustekinumab in the therapy of chronic plaque psoriasis.Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions.
P2860
Q24596756-B7D4182D-C341-4D2F-AD51-D3AB42697FCFQ24629783-4AEF83C5-CD22-424D-83FD-275C6734F304Q27013600-7DE61C61-902A-45A9-B86A-B32B587C1308Q28240342-285E8BF2-92D0-4BDA-AB14-A1BC190E4B56Q28280687-1E1D23F9-CAE9-4DF7-9583-9F5210E556E3Q28482161-8BC55381-91BC-4040-BE9E-BEB5ADE9D1F8Q28755865-9EBA7D93-2F81-4BD8-AF19-A8C63F9AB123Q30445672-74D70A2C-D07C-479B-8F42-E85EA82FB00CQ30525640-6E552B78-2F9C-4B80-A15E-71F8D9681FEEQ31151707-C6D060EE-A1FF-4A0C-8B7C-9D19E44D82FAQ33573621-BEECCDED-2BD8-41FB-A596-581B9E50773CQ33760897-AEBEED24-ABA0-44C2-9D22-18B92EC0871DQ33892602-53FEFD67-A412-4E7B-8C29-9EB037EC88D2Q33911969-151A6D2B-2C3A-4D11-970B-A3B8F38542C0Q33990291-1AB4AE5E-C0D3-4712-930D-AB51132F932BQ34041797-0483C867-B8AF-42A4-B021-C9214FFD56A3Q34112840-73B983A6-6320-47AF-8946-BE97D1809135Q34199603-F59E4D3E-C4E4-477A-98C9-DB8D63F3B049Q34422017-C3AE1B57-0944-4867-9E2B-032E52475B6AQ34634463-B2DF7DDC-4442-40C5-9E18-DDA891E04C66Q35207094-E8807698-E2AF-4880-AFE5-99F572300415Q35820734-4408C8EF-4DAF-4958-BF37-8DB4156F641AQ36151081-4B00BD08-0FC7-4764-AA8E-0AC3B90D6B56Q36252966-877A3657-C634-423A-8C33-169F03F49013Q36383605-74D70E38-8D42-4E60-8D74-07BF7E4CDDA4Q36479820-C797CB2E-A1E1-499C-9AF8-323C17EF2033Q36742020-D44315F9-DFCE-41B9-AD24-D3DB19AC8466Q36767393-90619E35-8C6E-4A4C-BFB5-1944E8598BB6Q36807407-95ED24D8-3C5E-402C-80C6-DA98F8726FB4Q36942960-CEDFD44D-F7D6-43CD-BC33-B1A9EED63617Q36993315-D9D22830-627C-4BBE-8F15-B4755BB453E5Q37019141-65D45BF3-61EF-4502-AB38-D3707B41FAF1Q37027598-3DC61D82-CF22-40DD-958B-67BC08B27F2BQ37051513-C97A3A52-304A-4586-9B42-DD4F9A61D98CQ37164125-4ED3C4B9-7DFE-4DA1-B2B4-357D3D67927FQ37202513-DEBB791A-DDCF-4718-B103-790B52983FDAQ37216488-8D8715AF-B007-4D78-BC5D-86A0E78A934CQ37217449-294DBEE5-2A92-4927-992F-AF41BBF53554Q37303190-5C4BEC42-E9AC-4F2E-B199-F7B2096D56FEQ37369062-7C8B7365-A6EE-400A-B1B6-92FE2DDA4A9A
P2860
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
An anti-IL-12p40 antibody down ...... and IL-12/IL-23 in psoriasis.
@en
An anti-IL-12p40 antibody down ...... and IL-12/IL-23 in psoriasis.
@nl
type
label
An anti-IL-12p40 antibody down ...... and IL-12/IL-23 in psoriasis.
@en
An anti-IL-12p40 antibody down ...... and IL-12/IL-23 in psoriasis.
@nl
prefLabel
An anti-IL-12p40 antibody down ...... and IL-12/IL-23 in psoriasis.
@en
An anti-IL-12p40 antibody down ...... and IL-12/IL-23 in psoriasis.
@nl
P2093
P1476
An anti-IL-12p40 antibody down ...... and IL-12/IL-23 in psoriasis.
@en
P2093
Alice B Gottlieb
Bart Frederick
Catharine L Kauffman
Charles E Pendley
Daniel E Everitt
Eiko Toichi
Gisela Torres
Kevin D Cooper
Mary Ann Mascelli
Nancy Aria
P304
P356
10.4049/JIMMUNOL.177.7.4917
P407
P577
2006-10-01T00:00:00Z